Baudax Bio, Inc. (BXRX): Price and Financial Metrics

Baudax Bio, Inc. (BXRX): $0.60

-0.01 (-0.96%)

POWR Rating

Component Grades













Add BXRX to Watchlist
Sign Up

Industry: Biotech


of 506

in industry


  • BXRX scores best on the Sentiment dimension, with a Sentiment rank ahead of 28.82% of US stocks.
  • BXRX's strongest trending metric is Momentum; it's been moving down over the last 47 weeks.
  • BXRX ranks lowest in Quality; there it ranks in the 1st percentile.

BXRX Stock Summary

  • BXRX's went public 1.84 years ago, making it older than just 2.96% of listed US stocks we're tracking.
  • Equity multiplier, or assets relative to shareholders' equity, comes in at -4.25 for Baudax Bio Inc; that's greater than it is for just 2.76% of US stocks.
  • Shareholder yield, a measure of how much is returned to shareholders via dividends and share repurchases, for BXRX comes in at -119.04% -- higher than that of just 1.68% of stocks in our set.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Baudax Bio Inc are ECOR, NVRO, EKSO, ACRX, and SIBN.
  • BXRX's SEC filings can be seen here. And to visit Baudax Bio Inc's official web site, go to

BXRX Valuation Summary

  • BXRX's EV/EBIT ratio is -1; this is 103.41% lower than that of the median Healthcare stock.
  • Over the past 22 months, BXRX's price/sales ratio has gone NA NA.
  • BXRX's price/earnings ratio has moved down 0.5 over the prior 22 months.

Below are key valuation metrics over time for BXRX.

Stock Date P/S P/B P/E EV/EBIT
BXRX 2021-08-31 98.0 -11.6 -1.4 -1.0
BXRX 2021-08-30 94.8 -11.3 -1.4 -1.0
BXRX 2021-08-27 94.1 -11.2 -1.4 -0.9
BXRX 2021-08-26 104.8 -12.4 -1.5 -1.1
BXRX 2021-08-25 105.7 -12.6 -1.5 -1.1
BXRX 2021-08-24 100.2 -11.9 -1.4 -1.0

BXRX's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • BXRX has a Quality Grade of F, ranking ahead of 1.38% of graded US stocks.
  • BXRX's asset turnover comes in at 0.008 -- ranking 78th of 80 Healthcare stocks.
  • 500 - Internal server error

The table below shows BXRX's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.008 -3.584 -4.211
2021-03-31 0.010 -2.695 -14.661
2020-12-31 0.007 -2.513 28.623
2020-09-30 0.006 -1.854 20.273
2020-06-30 0.006 -0.862 40.097
2019-12-31 0.000 NA 4.262

BXRX Price Target

For more insight on analysts targets of BXRX, see our BXRX price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $2.00 Average Broker Recommendation 1.25 (Strong Buy)

BXRX Stock Price Chart Interactive Chart >

Price chart for BXRX

BXRX Price/Volume Stats

Current price $0.60 52-week high $3.56
Prev. close $0.60 52-week low $0.50
Day low $0.58 Volume 1,250,600
Day high $0.62 Avg. volume 3,846,635
50-day MA $0.62 Dividend yield N/A
200-day MA $1.02 Market Cap 50.57M

Baudax Bio, Inc. (BXRX) Company Bio

Baudax Bio, Inc., a pharmaceutical company, develops and commercializes products for hospital and other acute care settings. Its lead product candidate is intravenous form of meloxicam, a non-opioid that has completed Phase III clinical trials for the management of moderate to severe pain; and is in the Phase IIIb clinical trials in colorectal surgery and orthopedic surgery patients to assess opioid consumption, pain intensity, and length of hospital stay with associated pharmacoeconomic parameters. The company's early-stage product candidates includes RP1000, an intermediate-acting neuromuscular blocking agent (NMBA) that is in phase I clinical trial; and RP2000, an ultrashort-acting NMBA, which is in pre-clinical trial; and a reversal agent, as well as Dex-IN, a proprietary intranasal formulation of dexmedetomidine. The company was incorporated in 2019 and is based in Malvern, Pennsylvania.

BXRX Latest News Stream

Event/Time News Detail
Loading, please wait...

BXRX Latest Social Stream

Loading social stream, please wait...

View Full BXRX Social Stream

Latest BXRX News From Around the Web

Below are the latest news stories about Baudax Bio Inc that investors may wish to consider to help them evaluate BXRX as an investment opportunity.

Baudax Bio to Participate in the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit

MALVERN, Pa., Sept. 16, 2021 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX), a pharmaceutical company focused on commercializing and developing innovative products for acute care settings, today announced that Gerri Henwood, the Company’s President and Chief Executive Officer, will participate in a virtual fireside chat at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit on Wednesday, September 22, 2021 at 1:15 p.m. ET. A live webcast of the fireside chat will be available on t

Yahoo | September 16, 2021

Baudax Bio to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

MALVERN, Pa., Sept. 07, 2021 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX), a pharmaceutical company focused on commercializing and developing innovative products for acute care settings, today announced that Gerri Henwood, the Companys President and Chief Executive Officer, will give a corporate presentation at the H.C. Wainwright 23 rd Annual Global Investment Conference, being held virtually September 13-15, 2021.

Intrado Digital Media | September 7, 2021

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday

It's time for another eventful day of trading and we're kicking it off with a look at the biggest pre-market stock movers for Thursday.

William White on InvestorPlace | September 2, 2021

Do Options Traders Know Something About Baudax Bio (BXRX) Stock We Don't?

Investors need to pay close attention to Baudax Bio (BXRX) stock based on the movements in the options market lately.

Yahoo | August 25, 2021

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday

Good morning, investor!

William White on InvestorPlace | August 24, 2021

Read More 'BXRX' Stories Here

BXRX Price Returns

1-mo 18.34%
3-mo -21.57%
6-mo -58.04%
1-year -82.61%
3-year N/A
5-year N/A
YTD -40.59%
2020 -85.40%
2019 N/A
2018 N/A
2017 N/A
2016 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.7226 seconds.